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ABSTRACT 
INTRODUCTION:  Benign prostatic hyperplasia (BPH) is a highly prevalent disease that inflicts 
significant inconvenience upon men afflicted with it and, if left untreated, can progress to 
complete obstruction resulting in uremia and kidney failure.  The purpose of this paper is to 
systematically review the published evidence regarding the use of two injectable agents, 
botulinum toxin (BT) and absolute ethanol (AE), used intraprostatically and to assess their 
effectiveness as a potential minimally invasive treatment for benign prostatic hyperplasia.  
METHODS:  A comprehensive literature search of several databases including MEDLINE was 
performed, and articles were selected based on their fitting predefined inclusion and exclusion 
criteria.  These studies were evaluated based on four research questions examining the efficacy 
of the treatment in relieving subjective and objective elements of BPH, its safety, and 
comparisons with traditional treatment options.  RESULTS:  A total of five studies using BT and 
six using AE was selected for inclusion in the review.  The studies varied significantly in the 
quality of their design and implementation.  Subjective relief of the BPH symptoms was 
measured in every study, while resolution of the different objective signs of BPH was measured 
to a varying degree in each study.  Very few significant safety issues were reported in any of 
these studies.  No study using either agent directly compared the therapeutic effects of 
intraprostatic injection to a traditional therapy for BPH.  CONCLUSIONS:  Published studies 
indicate that intraprostatic injection of AE and BT are safe and effective treatments for BPH.  
Whether these treatments are superior to traditional interventions for BPH in efficacy or cost 
remains to be determined, and before this treatment modality can be recommended for use in 
routine practice, blinded, high quality, controlled randomized trials testing them must be 
performed. 
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INTRODUCTION 
Benign prostatic hyperplasia (BPH) is a condition characterized by enlargement of the 
prostate gland leading to obstructive urinary symptoms.  It occurs naturally as a man ages; the 
prevalence of BPH has been suggested to be as high as 50% in men age 51 to 60 and over 80% 
in men aged 80 or older.1  Often the clinical presentation of BPH is distinguishable from 
carcinoma of the prostate underscoring the fact that this is not a malignant condition and does not 
predispose a man to developing prostate cancer.  Although the etiology of BPH is complex, it 
appears that the most important factor is androgenic stimulation, that is, trophic effects of the 
hormone dihydrotestosterone (DHT), a metabolite resulting from the conversion of plasma free 
testosterone by 5-alpha-reductase type 2 (5-AR) that takes place within the gland.  Studies of 
men born with a genetic deficiency of this enzyme have proven the critical role of DHT in the 
development of the prostate.2   
The symptoms of BPH are thought to result from two distinct processes that occur within 
the gland: a “static” process related to prostatic overgrowth as well as a “dynamic” process 
associated with smooth muscle contraction.  As a man ages, accumulated effects of years of 
DHT stimulation cause prostatic enlargement that strains the tough outer capsule surrounding the 
gland and compresses the urethra carrying urine through it from the bladder.  Meanwhile alpha-1 
adrenergic receptors populating the prostate gland and bladder neck mediate smooth muscle 
contractions that further obstruct the urethra.  The resulting urinary stasis irritates the bladder and 
leads to the development of a third, extraprostatic component of BPH – bladder detrusor muscle 
dysfunction.3  The bladder becomes sensitive to even small amounts of urine and through 
involuntary contractions of its detrusor muscle the obstructive process is perpetuated. 
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The clinical manifestations of these processes known as lower urinary tract symptoms 
(LUTS) include obstructive complaints such as hesitancy (difficulty initiating urination) and a 
decreased force of the urinary stream, as well as irritative symptoms such as urgency (the 
sensation of imminent urination) and an increased frequency of urination both during the day as 
well as at night (called nocturia).  These symptoms frustrate patients and can lead to a significant 
decrease in their quality of life.  Most often this decreased quality of life leads a man to seek 
therapeutic relief of his disease, however, if left untreated BPH can cause urinary stasis and 
subsequent development of urinary tract infection and calculi, renal dysfunction, hydronephrosis, 
and eventual renal failure. 
 
Diagnosis and characterization of disease severity 
The recommended diagnostic workup for BPH includes an extensive medical history as 
well as a detailed physical exam that includes a digital rectal exam.4, 5  Initial evaluation should 
rule out other possible conditions such as urinary tract infection or bladder cancer (irritative 
voiding symptoms with concomitant abnormal urinalysis) and urethral stricture (a history of 
prior instrumentation, trauma, or previous infection along with a stricture palpable on exam or 
visible on imaging studies).  The American Urological Association (AUA) recommends that men 
with greater than a ten year life expectancy be offered serum prostate specific antigen (PSA) 
testing to aid in excluding prostate cancer.  However, the diagnostic value of this test is 
complicated by the fact that conditions such as benign prostatic enlargement or prostatic or 
bladder infection can also increase serum PSA, and thus clinicians should consider further 
measurements such as PSA velocity or serum Free PSA to help distinguish between the 
conditions.  Because of the uncertainty of some serum PSA values, the decision of whether to 
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test for this should be made by the patient and doctor together.  In men with symptoms or signs 
of particularly severe BPH, evaluation of renal function via serum electrolytes, BUN, and 
creatinine measurements are necessary elements of the diagnostic work up.   
 
Subjective measurements of disease severity 
The severity of BPH can be assessed subjectively through the use of either the AUA 
symptom score or the International Prostate Symptom Score (IPSS), each of which is quantified 
after the completion of a seven-question survey concerning the extent of a patient’s LUTS and its 
impact on his quality of life.5, 6  The disease is then classified as either “mild” (score of 0-7), 
“moderate” (score of 8-19), or “severe” (score of 20-35).  An additional inquiry used to 
characterize the impact of the symptoms is the BPH-specific quality of life (QOL) question.  
This question is scored on a scale from 0 to 6 (“delighted” to “terrible”) and asks the patient: “If 
you were to spend the rest of your life with your urinary condition just the way it is now, how 
would you feel about that?”  Another validated measure of subjective impact of the disease, the 
BPH Impact Index (BII), can be used to measure the effect of the disease on a patient’s activities 
of daily living.7  The results of these validated questionnaires help guide treatment decisions. 
 
Objective measurements of disease severity 
Diagnostic testing should be used to evaluate objectively the severity of BPH, especially 
in those patients considering invasive treatment.  One such test is the measurement of the post-
void residual (PVR) volume, that is, the volume of urine remaining in a man’s bladder after 
micturition.  This can be done easily in the clinic via transabdominal ultrasonography.  As a 
patient’s outlet obstruction increases, so does his post-void residual volume, yet due to intra-
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patient volume variability from one measurement to the next, only large volumes (>300 ml) are 
thought to be predictive of bladder dysfunction and the potential for decreased response to 
treatment.  A second tool used in characterizing BPH is uroflowmetry, a measurement of urine 
flow rate over time.  The most relevant measure generated by this is the peak maximal flow rate 
designated as Qmax.  Urine Qmax values greater than or equal to 15 ml/sec with a voided volume 
of 150 ml suggest normal physiology, while values lower than 10 ml/sec suggest some form of 
obstruction.  Historically uroflowmetry has been an office-based procedure, however some have 
questioned whether urinating once in a clinical setting is an accurate representation of a man’s 
normal voiding.  Recently home-based uroflometry methods have been shown to be a reliable 
alternative for measuring Qmax that is both acceptable to patients and able to provide more 
representative information due to its ability to take multiple measurements.8, 9  Further testing 
used in select situations includes the estimation of prostate volume (PV) via transrectal 
ultrasonography, measurement of bladder pressure during voiding by pressure-flow studies, and 
direct visualization of the lower urinary tract through cystoscopy. 
 
Current treatment options 
Although the decision to treat BPH takes into account all of these measurements, the 
most useful in stratifying patients to treatment modalities is the AUA symptom score.  Unless a 
patient with “mild” or asymptomatic “moderate” disease is in danger of developing serious 
complications from BPH, generally he can be managed conservatively until the symptoms 
become disruptive to his daily life.  These patients are encouraged to make lifestyle 
modifications such as decreasing fluid intake before going to sleep and decreasing the use of 
diuretic substances such as caffeine and alcohol.  Yearly follow-up examinations are used to 
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reevaluate the degree of intrusion the symptoms have on the patient’s life.  Some men adapt to 
these symptoms over time and continue conservative management for many years, however, 
prospective studies in men undergoing observation have suggested that many of these men 
eventually seek some form of treatment for their BPH.  One study of men with moderate BPH 
symptoms estimated that 36% sought surgical treatment within 5 years.10   
Active treatment options for BPH include both medical and surgical interventions, and 
each is associated with side effects and morbidities.  Pharmacologic treatment of BPH has 
become a multimillion-dollar industry (see Addendum for discussion of marketing and cost of 
medical therapy for BPH) and consists of two distinct classes of drugs, alpha-adrenergic 
antagonists (“alpha blockers”) and 5-alpha-reductase inhibitors (ARI).  Although each has 
specific indications for use, a patient who is not receiving adequate relief from one class alone 
can be prescribed the other to work in combination.  Long-term use of such combination therapy 
has recently been shown to reduce the risk of BPH progression more than with one agent alone.11   
 
Medical treatment: Alpha-adrenergic antagonists  
Alpha-adrenergic antagonists such as tamsulosin, alfuzosin, terazosin, and doxasozin 
block alpha receptors within the prostate and bladder, inhibiting smooth muscle contractions and 
relieving obstructive symptoms by decreasing resistance to the passage of urine.  These 
medications are often used as first-line treatment for men with BPH due to the rapidity with 
which they can reduce symptoms.  They require daily administration, however, and often times 
the starting dose must be titrated upward over several weeks time in order to provide adequate 
relief.  Within this group are several different medications that differ from one another based on 
their affinity for the different subtypes of alpha-adrenergic receptors.  Those that are less 
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selective (such as terazosin and doxasozin) can interfere with blood pressure regulation in 
addition to their effects in the prostate, leading to systemic cardiovascular side effect such as 
dizziness, headache, asthenia, and orthostatic hypotension.  To offset these effects, men are 
advised to begin taking them before going to sleep (see Addendum for further discussion of side 
effects of treatment with alpha-adrenergic inhibitor). 
 
Medical treatment: 5-alpha-reductase inhibitors 
The second class of medications used to treat BPH is the 5-alpha-reductase inhibitors, 
finasteride and dutasteride.  These drugs block conversion of testosterone to dihydrotestosterone 
within the prostate, eliminating the trophic effects of DHT and shrinking the gland.  Therefore 
these medications are thought to be appropriate only for men with proven prostatic enlargement.  
Treatment requires an extended amount of time before the relief of symptoms; maximum 
effectiveness often does not begin until at least 3-6 months of daily use.  Due to the disruption of 
the androgen axis caused by these drugs, their side effect profiles are hormonal in nature and 
include sexual consequences such as loss of libido and erectile dysfunction, although these are 
uncommon (see Addendum for further discussion of side effects from taking 5-alpha-reducatase 
inhibitors).  Another concern regarding treatment with ARI relates to screening for prostate 
cancer.  Use of these medications has been shown to lower serum PSA levels which can 
complicate future screening for prostatic malignancy.  With this in mind, some have suggested 
PSA levels be multiplied by a factor of 2 to correct for treatment of less than 24 months, and by 
2.5 for longer use.12   
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Surgical treatment 
BPH can also be treated surgically, and these interventions are divided broadly into 
invasive and minimally-invasive procedures.  The oldest invasive treatment is the open simple 
prostatectomy which involves removal of the gland under general anesthesia through an 
abdominal incision.  The most common invasive intervention and the current gold-standard 
treatment is the transurethral resection of the prostate (TURP), which also can require general 
anesthesia and at least a day of hospitalization, as well as post-procedure catheterization.  A 
small number of patients are at risk of developing TUR syndrome, a consequence of excessive 
absorption of the irrigation fluid used during the procedure that which can lead to severe 
neurologic and pulmonary complications.  A newer less invasive technique, laser prostatectomy, 
is performed similarly to the traditional TURP except with the use of laser pulsing to vaporize 
the tissue as opposed to the diathermic cutting with coagulation approach used in TURP.  A 
recent report has suggested that patients receiving the laser TURP have a quicker recovery period 
than those receiving a traditional TURP,13 and often times this procedure can be done in an 
outpatient setting.  However, the patients receiving the laser treatment had a higher rate of re-
operation than did those receiving the traditional treatment.  Other minimally invasive 
interventions include transurethral needle ablation of the prostate (TUNA) and transurethral 
incision of the prostate.   These therapies have shown to be adequate in the short term 
management of BPH, although the symptom relief is not nearly as large as with the traditional 
TURP, and the need for re-treatment is much higher.   
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Intraprostatic injection: an experimental treatment option 
Although both medical and surgical treatments for BPH have proven to be effective 
means for providing symptomatic relief from the condition, each is associated with significant 
negative aspects.  Medical treatments entail the potential for systemic side effects, a risk 
especially salient in a population of older men who often possess other comorbidities and take a 
host of other medications.  Furthermore, the cost of having to take a daily medication for the 
treatment of BPH can lessen a patient’s willingness to undergo treatment with these medications.  
A recent inquiry showed the price of a year’s worth of 5 mg finasteride to be approximately 
$800.14   Besides the monetary cost of purchasing medication, also significant are the opportunity 
cost and disutility of taking a pill each day.  Moreover, therapeutic success is not assured.  A 
retrospective study examining patients treated with alpha-blockers over a 3-year period 
suggested that treatment is not always effective, finding respective re-treatment rates of patients 
with mild, moderate, and severe lower urinary tract symptoms of 27%, 33%, and 70%.15  
Surgical treatments for BPH generally have a high rate of short-term symptom resolution, yet 
carry the risk of side effects such as impotence, incontinence, and retrograde ejaculation.  
Advanced age or comorbid conditions can also prevent some patients with BPH from being 
eligible for surgical interventions.  Surgical intervention is also more expensive than medical 
therapy, both to the patient and healthcare systems, given the costs associated with equipment, 
operating room time, anesthesia, and hospitalization.  While several authors have examined the 
cost effectiveness of traditional treatments for BPH,16-18 a significant amount of research must be 
done in this area.  One group did find that α-blockers and TURP are the most cost-effective 
alternatives, for BPH patients with moderate and severe symptoms, respectively.16  These 
limitations of current therapeutic choices for BPH has encouraged investigation into cheaper, 
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less invasive alternatives for treating the condition that do not have the high risk profiles of 
current treatment methods. 
One alternative treatment modality for benign prostatic hyperplasia that has attracted a 
great deal of interest over the last decade is that of intraprostatic injection.  However, as Plante 
and colleagues point out in their review of the history of the intervention,19 the interest in directly 
treating prostatic disease percutaneously is not a recent phenomenon but rather stems from 
nearly two hundred years ago when an English surgeon, Dr. B.C. Brodie, suggested treating 
prostatic abscesses directly via transperineal puncture. Over the next century methods of directly 
accessing the prostate and treating prostatic infection became better characterized, and near the 
turn of the 20th century an English surgeon serving the Viceroy of India, Sir James Roberts, 
began treating the obstructive symptoms of prostatic enlargement with intraprostatic injections of 
solutions containing carbolic acid, glacial acetic acid, and glycerin.  Modern interest in 
intraprostatic injections as a method of treating BPH was sparked by the published reports of 
Talwar and Pande in 1966, in which the two surgeons recounted their experience treating a series 
of 188 consecutive cases using the intervention taught to them by one of Robert’s trainees.20  For 
several years after this, investigators enthusiastically pursued similar procedures, but soon were 
forced to abandon the technique due to complications and inconsistent results.21   
 
Absolute Ethanol injection 
Recent interest in intraprostatic injection as a treatment modality for BPH was renewed in 
1988 after Littrup et al. published results investigating transrectal ultrasound-guided 
intraprostatic ethanol injections in canine prostates as a potential treatment for prostatic 
adenocarcinoma.22  This group showed that transperineal injection of ethanol was effective in 
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causing necrosis of the prostate gland but at the cost of damaging peripheral structures in the 
lower urinary tract including the urethra, external urinary sphincter, and bladder mucosa.  On a 
cellular level, ethanol is thought to exert its effect by diffusing into cells and causing dehydration 
that produces protein degeneration, membrane lysis, fibrosis, and thromboembolic occlusion of 
local blood vessels.21, 23, 24  However the morbidity shown in this particular study was more a 
function of the injection technique rather than the agent itself, and future studies undertaken to 
examine the potential of ablation via intraprostatic ethanol injection showed promising results.  
Zvara25 and Levy23 demonstrated that both transurethral and transrectal intraprostatic injections 
of absolute ethanol caused coagulative necrosis and hemorrhage within the canine prostate 
without damage to the bladder or external sphincter.  These observations along with favorable 
results using injectable ethanol as a chemoablative agent in the treatment of several conditions 
including hepatocellular carcinoma and renal cysts26-30 have encouraged investigators to evaluate 
further the potential of intraprostatic ethanol to treat BPH in humans. 
 
Botulinum Toxin injection 
Another injectable agent that has received attention recently for its potential to treat 
human disease is botulinum toxin type A (BT).  This neurotoxin produced by the anaerobic 
bacteria Clostridium Botulinum acts by inhibiting the release of acetylcholine at the 
neuromuscular and neuroglandular junctions causing muscle relaxation and a long-lasting 
reversible paralysis.  Some have called it “the most potent toxin known to man.”31  At higher 
concentrations it has also been found to affect other neurotransmitters as well, including 
norepinepherine, dopamine, serotonin, and γ-aminobutyric acid.32  In 1989 the US Food and 
Drug Administration (FDA) licensed the use of injectable botulinum toxin type A for treatment 
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of skeletal muscle disorders, and since then it has been used effectively to treat a host of 
disorders including achalasia, cervical dystonia, axillary hyperhidrosis, and strabismus.  The 
most well-known usage of the drug, however, remains its applications in cosmetic surgery for 
treating wrinkles.  The formulation of the toxin most commonly used in the US is known as 
Botox and is produced by Allergan.  Lately botulinum toxin has found a place in the therapeutic 
armamentarium of urologists as well.  Recent reviews have shown Botox to be a useful treatment 
for such lower urinary disorders as detrusor-sphincter dyssynergia, urge incontinence, and 
detrusor overactivity.33, 34   
Significant interest in the therapeutic potential of Botox as a treatment for benign 
prostatic hyperplasia has also developed.  The use of the toxin within the prostate has its roots in 
a 1998 study conducted by Doggweiler et al. in which botulinum toxin was shown to reduce the 
weight and volume of prostate glands in rats after intraprostatic injection.  Histologic analysis 
showed generalized atrophic changes as well as increased apoptotic bodies throughout the gland 
without any signs of local or systemic toxicity.  The investigators theorized that treatment with 
Botox chemically denervated the prostate gland and removed trophic neural influence from it.  
They further hypothesized that such an intervention in humans could alleviate the static 
component of BPH and the obstructive symptoms caused by it.   
Subsequent studies in both rats35 and dogs36 have confirmed these results and 
demonstrated a down-regulation in the expression of alpha-1 adrenoreceptors in the prostate as 
measured by Western blot.35  This suggests another potential route through which therapeutic 
botulinum toxin could alleviate the symptoms of the hyperplastic prostate:  prevention of the 
dynamic component of BPH by decreasing smooth muscle contraction.  Finally, after Cui et al. 
showed that pretreatment with Botox led to a decrease in local glutamate release in a rat model 
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of formalin-induced pain,37 a recent study using a rat model of nonbacterial prostatitis induced 
by intraprostatic injection of capsaicin demonstrated that rats pretreated with Botox showed a 
significant reduction in pain-related behavior as well as a decrease in inflammatory changes 
within the prostate gland.38  These studies suggest a potential role for botulinum toxin in 
mediating nociceptive pathways and reducing the irritative component of BPH.  With these 
results in mind, several studies have now been performed investigating the potential effects of 
botulinum toxin in treating benign prostatic hyperplasia in humans. 
 
Objective 
Benign prostatic hyperplasia is a highly prevalent disease that inflicts significant 
inconvenience upon the large majority of men afflicted with it.  If left untreated, BPH can 
progress to complete obstruction resulting in uremia and kidney failure.  As current treatment 
options for BPH are expensive and can result in morbidity and disutility to men choosing them, 
large efforts have been made into finding alternatives to conventional modalities that are 
effective in relieving a patient’s symptoms.  The idea of treating BPH via intraprostatic 
injections is appealing, and recently two agents, absolute ethanol and botulinum toxin, have 
received a considerable amount of interest from the scientific community in light of the promise 
they have shown in treating prostatic disease in animal studies.  The purpose of this paper is to 
systematically review the evidence regarding the use of these two therapeutic interventions in 
men with BPH and to assess their effectiveness as a potential minimally invasive treatment for 
benign prostatic hyperplasia. 
McKim 13 
METHODS 
 
Key Questions: 
The following research questions were examined: 
Regarding intraprostatic injections of absolute ethanol and botulinum toxin as potential therapies 
for benign prostatic hyperplasia: 
1) Does the agent reduce a patient’s subjective symptoms of BPH? 
2) Does the agent reduce objective signs of BPH? 
3) Has the agent been tested directly against accepted forms of BPH treatment? 
4) What are the treatment comorbidities, harms, and negative side effects associated 
with the agent? 
 
Study Inclusion and Exclusion Criteria: 
Based on the key questions, a set of inclusion and exclusion criteria was developed.  The 
novelty of each of the techniques necessitated a lenient set of inclusion criteria as the goal was to 
assess all possible reported studies.  Study populations included human males aged 50 years or 
older of any race, ethnicity or cultural group.  The studies could be conducted anywhere in the 
developed world and all studies published since 1980 were accepted.  This was judged to be an 
adequate time period to ensure that all studies using botulinum toxin were included (as it was 
first approved by the FDA in 1989), as well as ensuring that all studies were current enough to 
have technologic means of visualizing the prostate before injection.  Any study design was 
accepted.  The dosage and route of injection had to be clearly stated, and all studies must have 
included at least one month of follow-up.  All studies must have reported the patient’s subjective 
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BPH symptoms using a validated scale (AUA Symptom Score Index or IPSS).  All results must 
have been reported in absolute rather than relative terms. 
 
Study population: 
Human subjects 
Male, aged 50 years or older 
Any race, ethnicity, or cultural group 
Study settings and geography: 
Studies conducted in the developed world including North and South America, 
Japan, and Europe. 
Time Period: 
  Published from January 1980 to October 2007 
Publication Criteria: 
  English language only 
  Articles in print or “e-published” stage 
Abstracts from scientific meetings were reviewed but were not assigned evidence 
ratings 
Admissible Evidence (study design and other criteria): 
  Any type of study design 
Follow-up period must be stated clearly; results must include data from at least 1 
month post-intervention 
The prostate was visualized before injection (using either cystoscopy or 
transrectal ultrasound) 
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Method of injection was clearly stated in the published article 
Dosage of agent was clearly stated in the published article 
Subjective BPH symptom score or quality of life score was reported using a 
validated scale 
Results were reported in absolute terms, not solely in relative (percentage) terms 
 
Literature Search and Retrieval Process: 
Databases and Search Terms 
Three databases were searched for potential studies to be included in this systematic review.  The 
MEDLINE database was searched using combinations of the following search terms:  
1) Agent: Ethanol 
“Ethanol” [MeSH]; “Prostatic Hyperplasia” [MeSH]; “Injections” [MeSH]; “prostatic 
ablation”; “ethanol ablation”; “alcohol ablation”; “percutaneous ablation”; “prostate 
ablation”; “prostate”; “ethanol”; 
2) Agent: Botulinum 
“Botulinum Toxin Type A” [MeSH]; “Botulinum Toxins” [MeSH]; “Prostatic 
Hyperplasia” [MeSH]; “prostate” 
 
The Web of Science and BIOSIS Previews databases was searched using combinations of the 
following search terms: 
1) Agent:  Ethanol 
“ethanol”, “alcohol”, “prostate”, “benign prostatic hyperplasia”, “chemoablation”, 
“intraprostatic”, “injection” 
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2) Agent:  Botulinum Toxin 
“Botulinum”, “Botox”, “prostate”, “benign prostatic hyperplasia”, “intraprostatic”, 
“injection” 
 
To identify additional relevant literature, the reference lists of identified articles were hand 
searched, as were the electronic indices of the following journals using the search terms 
mentioned above: 
Journal of Urology (1/1995 – 4/2007) 
Urology (1/1973 – 4/2007) 
European Urology (1/2002 – 4/2007) 
European Urology Supplements (1/2002 – 4/2007) 
The Prostate (1/1980 – 4/2007) 
Prostate Cancer & Prostatic Disease (9/1997 – 4/2007) 
Journal of Endourology (9/2000 – 4/2007) 
 
Additionally, electronic abstracts from the following annual scientific meetings were searched: 
 American Urological Association (2002 – 2007)  
Endourological Society (2001 – 2006)  
 European Association of Urology (2002 – 2007) 
Société Internationale d'Urologie (2004, 2006) 
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Article Selection and Review 
The author evaluated abstracts of published articles for fulfillment of the aforementioned 
criteria.  If an abstract met the criteria, the full text of the article was obtained and reviewed for 
inclusion in the study.  Because abstracts from scientific meetings did not go through the peer-
review process, those meeting inclusion criteria were not reviewed in this paper but are included 
in the Addendum (Table 9). 
 
Evaluation of Study Quality: 
 The quality of the selected eleven studies (six for the ethanol intervention and five for the 
botulinum toxin intervention) was evaluated as detailed in Table 3.  The author graded each 
study based on the fulfillment of five quality criteria:  the adequacy of the description of the 
source population (including a comprehensive discussion of inclusion and exclusion criteria), the 
clarity with which patient follow-up and flow was presented, whether data were collected 
adequately, whether data were analyzed appropriately, and whether statistical results were 
reported completely with p-values or confidence intervals.  These quality ratings were then 
converted to numeric scores using a 0-3 point scale checklist (0=poor, 1=fair, 2=good, 
3=excellent), and an overall quality score (0-15) was produced for each study, with a range from 
poor (0-3), fair (4-7), good (8-11), excellent (12-15). 
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RESULTS 
Systematic Review: 
The combined search strategies for the first agent, absolute ethanol, returned a combined 
845 articles.  Duplicates were removed and full texts were reviewed for 70 of these articles.  All 
studies as well as abstracts from national scientific meetings were compared to later publications 
from the same investigators to assess originality; abstracts or studies found to have been 
published later were excluded.  After this review, a total of six peer-reviewed articles were found 
to meet the inclusion/exclusion criteria and were included in this systematic review (Table 1).  
This group consists of five nonrandomized, interventional (“before-and-after”) studies39-43 and 
one randomized, unblinded interventional trial.44  
The combined search strategies for the second agent, botulinum toxin, returned a 
combined 111 articles.  Duplicates were removed and full texts were reviewed for 40 of these 
articles.  After this review, a total of five peer-reviewed articles were found to meet the 
inclusion/exclusion criteria and were included in this systematic review (Table 2).  This group 
consists of one randomized, double-blind, placebo-controlled interventional trial,45 three 
nonrandomized interventional (“before-and-after”) studies,46-48 and one randomized, unblinded 
interventional trial.49 
  
Subjective relief of BPH symptoms: 
 The selected studies differed in the period after injection over which subjective resolution 
of BPH symptoms was assessed.  Each study reported post-injection follow-up measurements at 
the six-month time point.  However, range of follow-up assessments reported varied from one 
month to thirty-six months post-treatment. 
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Symptom score (Table 4) 
All of the studies using absolute ethanol to treat BPH assessed subjective relief of BPH 
symptoms using either the IPSS41-44 or AUA symptom score.39, 40  Each study showed 
statistically significant decreases in mean symptom score as compared to baseline at every time 
point in which analysis was performed.  Decreases were seen as early as one month after 
treatment and as three years after treatment.  All but one study used statistical analysis.40  Four of 
the studies using botulinum toxin to treat BPH assessed subjective relief of BPH symptoms using 
either the IPSS46, 48, 49 or AUA symptom score.45 
 
Quality of life indices (Table 5) 
Four of the studies using injections of absolute ethanol41-44 and three of the studies using 
botulinum toxin46-48 measured disease-specific quality of life.  All of these studies found 
statistically significant differences in the mean disease-specific QOL index after treatment at 
each time point in which analysis was performed.  These differences were apparent as early as 
one month after treatment in groups receiving injections with each of the two different agents, 
and as late as three years in a group receiving injections with botulinum.  One study also 
measured the BPII and found statistically significant differences from baseline values in all 
groups at six months after treatment (results not shown).44   
 
Objective reduction in BPH signs: 
Prostate volume (Table 6) 
All of the studies included in this review estimated prostate volume in milliliters, grams, 
or cubic centimeters at baseline and at different time points throughout the study.  For ethanol no 
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study examined prostate volume at one month after treatment.  Three of the five studies that 
measured prostate volume at six months after injection and used statistical analysis found 
statistically significant reductions in the mean values as compared to baseline.41, 43, 44  Both of the 
studies that examined this at one year found statistically significant reductions.42, 43  The only 
study that looked at more distant effects found a significant reduction at two years that appeared 
to resolve at three years.42  With the botulinum toxin intervention, every study that estimated 
prostate volume and analyzed the results statistically found a statistically significant decrease at 
the one month,45, 46, 48, 49 three month,46-49 six month46-49 post-injection time points.  The only 
study which assessed these changes at a later time point found that the statistically significant 
decrease in prostate volume remained at one year after injection.48 
 
Post-void residual volume (Table 7) 
Four of the studies using ethanol measured post-void residual volume after injection.39, 41, 
42, 44  Six months was the only post-injection time point common to each of these studies.  The 
two largest studies42, 44 found a statistically significant decrease in PVR at this time point while 
the two smaller studies did not39, 41.  The study by Goya et al. found a statistically significant 
decrease in PVR at up to three years after injection with absolute ethanol.42  Treatment with 
botulinum toxin led to statistically significant decreases in PVR in two of the four studies 
measuring this variable at one month,45, 48 while at 6 months there were statistically significant 
decreases found in three of four studies.47-49  This effect diminished at one year in the only study 
assessing the outcome at that time point.48 
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Peak urinary flow (Table 8) 
All of the studies using intraprostatic ethanol that assessed changes in Qmax at one and 
three months post-injection and showed statistically significant increases at these times points.39, 
42, 43   At the one year time point, two of three studies found this statistically significant trend 
continued,42, 43 and the only study that assessed peak urinary flow rate at a later time point found 
statistically significant increases at both two and three years after injection.42  Three of the four 
studies using botulinum toxin found statistically significant increases in peak urinary flow at the 
one month post-injection time point.45, 46, 48  Similarly, all four studies using Botox that measured 
peak urinary flow at 3 and 6 months and analyzed results found statistically significant increases 
remained at those time points.46-49  The only study that looked at peak urinary flow at a more 
remote time point found the trend continued at one year post-injection as well.48 
 
 
Comparisons with other treatments for BPH 
Ethanol 
None of the studies using intraprostatic injections of absolute ethanol included a head-to-
head comparison with another accepted treatment for BPH.   
Botulinum Toxin 
None of the studies using botulinum toxin included a head-to-head comparison with 
another accepted treatment for BPH.  However, the study by Park et al.49 included a comparison 
at the one month time point between a group of patients receiving intraprostatic injection of 
botulinum toxin alone with those receiving both the injection of Botox as well as concomitant 
treatment with an alpha-adrenergic antagonist for one month.  This study found that while both 
total AUA/IPSS score (Table 4), quality of life (Table 5), and prostate volume (Table 6) were all 
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statistically significantly reduced from baseline values, the only significant difference between 
the two groups was in the response to the IPSS-5 question (p=0.034), which states “Over the past 
month, how often have you had a weak urinary stream?” 
 
Harms associated with intervention 
Ethanol 
 None of the studies using intraprostatic injection of absolute ethanol reported any 
significant harm associated with the intervention.  Several investigators monitored blood alcohol 
levels, but no evidence of systemic alcohol absorption was found with this intervention.  Most 
concerns were minor medical issues, including hematuria, irritative voiding symptoms, brief 
urinary retention, urinary tract infection, and pain.  In each study patients were left with a Foley 
catheter in place for approximately a week to reduce stress on the urinary tract.   
Botulinum Toxin 
None of the studies using botulinum toxin as an intraprostatic treatment for BPH reported 
any significant morbidity from use of the intervention.  Of principle concern was the possibility 
of systemic absorption of the toxin leading to conditions such as respiratory depression or 
hyposthenia; none of these studies reported any such systemic manifestations of the drug.  Many 
reports specifically mentioned the lack of urinary retention, incontinence, urinary tract infection, 
urethral strictures, or gross hematuria after the procedure. 
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DISCUSSION 
 
 Based on the published studies identified in this systematic review, intraprostatic 
injection of either absolute ethanol or botulinum toxin presents a promising option for treating 
men with symptomatic benign prostatic hyperplasia.  Each study included in this review 
quantified the subjective severity of a patient’s BPH using either the IPSS or AUA symptom 
score.  These surveys are the most useful tools clinicians have in determining when a patient 
should begin therapeutic intervention for his disease.  Regardless of the agent used, at every time 
point in each study included in this review a statistically significant difference in symptom score 
as compared to baseline was found.  Similarly, the quality of life index was reduced at every 
time point in every study for each agent.  These significant improvements in patients’ symptoms 
occurred as early as one month after injection for both agents, and persisted through extended 
follow-up periods of three years for absolute ethanol42 and one year for botulinum toxin.48  Both 
agents also demonstrated the ability to relieve objective signs of BPH as well, however with 
much more inter-and intra-agent variability than with the reductions in subjective symptoms.  
Both absolute ethanol and Botox were able to cause significant decreases in prostatic size, post 
void residual volume, and peak urinary flow rate.  The possibility that a single intraprostatic 
injection could prolong symptomatic relief of a patient’s BPH for an extended period of follow 
up is exciting, and it is likely that if given the choice many patients would be interested in this as 
a treatment option rather than taking a daily medication or undergoing more invasive surgical 
treatments for their disease. 
  When comparing intraprostatic injections to other accepted treatment modalities for BPH 
the potential advantages are numerous.  Perhaps the most significant of these is the ease with 
which this emerging modality can be performed.  As opposed to many of the other invasive 
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procedures for treating the disease, intraprostatic injection of ethanol or botulinum toxin can be 
done in a rapid and seemingly pain-free manner during a clinical encounter.  Further, the 
technique requires little accessory equipment, is easy to learn, and has a very low rate of 
complication.  These factors make it an ideal treatment in resource-limited areas where access to 
more advanced minimally invasive treatments accessories like the holmium laser or TUNA 
system is not available.  From the studies included here it also appears that these injections have 
a very low incidence of significant adverse events.  Finally, the cost of the intervention could be 
dramatically less than the cost of other invasive treatments for BPH or daily medications used to 
treat the disease.   All of these characteristics make intraprostatic injection an ideal treatment 
modality for patients with BPH, especially those who do not qualify for or who do not desire 
surgical intervention and do not wish to take daily medications for their condition. 
 However intraprostatic injection is associated with several disadvantages as compared to 
traditional treatment modalities for BPH.  The issue of durability is the most significant of these.  
While long-term data are lacking it is obvious from short-term studies that that the therapeutic 
benefits of injection eventually wear off over time, and thus patients undergoing injection 
therapy for BPH would require a series of follow-up injections in order to maintain therapeutic 
benefit.  This stands in sharp contrast to invasive treatments such as TURP, the effects of which 
can last for many years.  This lack of durability brings with it the additional disadvantage of the 
expense entailed in paying for multiple rounds of injection therapy.  Because none of the studies 
included in this review have post-injection follow-up data longer than one year for botulinum 
toxin and three years for ethanol, at this point it is impossible to know how often patients need 
repeat injections and the overall cost for such injections.   
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 Still questions remain with regards to both of the agents studied here.  Because none of 
the studies included here used any method of quantifying pain or discomfort associated with the 
intervention, it is impossible to know what level of pain or discomfort is actually associated with 
these therapies.  For absolute ethanol, which route of injection is superior, transurethral, or 
transperineal, is unclear.  Technically, the transurethral route is easier and thus more likely to be 
pursued by a larger number of urologists.  Savoca39 claims that the transperineal approach 
performed via guidance using transrectal ultrasound is “less traumatic,” while Plante41 touts the 
fact that the transurethral route “avoids capsular distortion” and potential leakage of ethanol.  
Because none of the studies using ethanol compared the two methods and because neither 
method produced significant side effects, it stands to reason that in experienced hands neither 
method is superior.  With regards to botulinum toxin, only one formulation of one form of the 
toxin was used (botulinum toxin type A, “Botox”).  While this is the form of the toxin used most 
frequently in other areas of clinical medicine, it is unclear whether other formulations of the type 
A toxin or other types of the toxin would be more successful in treating BPH. 
 This review has several limitations.  Because the clinical use of these interventions is still 
in its infancy, the published literature lacks high quality studies using these two agents.  The 
highest quality study for assessing an intervention is a double-blind, placebo-controlled 
randomized trial.  Two studies included here, Maria et al.45 and Park et al.,49 were randomized 
and methodologically sound, however all the other studies included in this review were 
interventional or “before and after” studies that were not blinded.  This allows for the possibility 
of bias on the part of both the study investigators and the patients, and because part of the effect 
of the intervention was measured via subjective elements (i.e. AUA score), a patient’s being 
aware of his receiving an intervention could bias his answers.  Furthermore, only the study by 
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Maria et al. included a control arm.  This is a serious flaw in the design of the other studies as 
only with a contemporary control group can a prospective study truly establish the effect of an 
intervention as directly compared to another.  With regards to the quality ratings of the studies 
included in this review, because the author was the sole assessor of study quality it is likely that 
the quality ratings would differ with the input of a second reviewer.  Finally, none of the studies 
reviewed here included a head-to-head comparison of intraprostatic injection with any other 
traditional treatments for BPH and thus it is impossible to know if this treatment modality is 
superior to other methods in treating symptomatic BPH.  Only when such studies are performed 
can conclusions be drawn about the efficacy of this modality and the appropriateness of its use. 
 In the studies reviewed here, both intraprostatic absolute ethanol and botulinum toxin 
demonstrated the ability to reduce subjective as well as objective features of BPH with limited 
amounts of associated morbidity and virtually no significant adverse effects.  However, for 
injection of either of these agents to become an accepted form of treatment for BPH, significant 
research must still be carried out.  After proving its viability in case reports and observational 
studies, the next step in the acceptance of a potential treatment option is large trials that assess 
both the safety and efficacy of the agent.  The results of such trial can then be used to identify 
patient populations best suited for the intervention, especially as compared to traditional 
therapies for BPH.  Data from longer follow-up periods also must be gathered so that the 
durability of these treatments can be established and optimal time points for repeat injections can 
be identified.  The Phase I/II trial of absolute ethanol injection presented here41 answers some of 
the questions regarding safety of this agent, however, the follow-up on this trial only went to six 
months and needs to be carried out further.  With regards to botulinum toxin, recently two 
separate randomized controlled trials have begun enrolling patients in order to examine the 
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potential of intraprostatic Botox as a treatment for BPH.50, 51  When these trials conclude it is 
likely that enough information will be available to decide if Botox is in fact a suitable treatment 
for men with symptomatic BPH.  Until then the results of the studies reviewed here will continue 
to encourage both physicians and patients that less invasive yet effective treatments for BPH are 
just around the corner. 
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ADDENDUM 
 
Marketing and Cost of Pharmacologic treatments for BPH  
Recently television viewers have been treated to a series of advertisements for certain 
pharmaceutical products depicting middle-aged men in the midst of hiking, kayaking, bicycling, 
or other recreational activities who face constant interruptions caused by their increased 
frequency of urination.  “Here’s to guys who want to spend more time having fun and less time 
in the men’s room,” one commercial states.52  These men are visibly distraught with their 
symptoms and situation until a quick visit to their doctor assures them that their “going problem” 
is really a “growing problem” known as BPH.  Viewers are relieved to see that after these men 
receive the advertised medical treatment for this “growing problem” they are once again able to 
enjoy a vast array of recreational and social activities without the constant disturbances caused 
by frequent urination.  This advertisement is just one of a handful aimed at the treatment of such 
symptomatic states at an estimated cost in 2006 to pharmaceutical companies of $238.8 million 
dollars, an increase of nearly 37% of what was spent in 2005.53  Furthermore, the prevalence of 
BPH and the disruptive nature of its symptoms ensure that such expenditures will continue to 
rise in the years to come.  
 
Side effects of Alpha-adrenergic inhibitors 
A review published in 2005 found that terazosin and doxazosin had a higher association 
with both dizziness and orthostatic hypotension than did alfuzosin or tamsulosin.54  A double-
blind study randomizing men to long-term usage of doxazosin (3652 person-years) or placebo 
(3489 person-years) showed statistically significant (p<0.05) differences, respectively, in 
incident rates of dizziness (4.41 vs. 2.29/100 person-years), postural hypotension (4.03 vs. 
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2.29/100 person-years), and asthenia (4.08 vs. 2.06/100 person-years).11  A systematic review 
and meta-analysis of studies in which men with BPH were randomly assigned to either daily 
alfuzosin or placebo for at least four weeks duration in men showed a statistically significant 
difference in the relative risk ratio between the respective groups in the percentage of men 
experiencing dizziness (2.04, 95% confidence interval: 1.29 – 3.22, from six studies looking at 
1298 men taking alfuzosin and 1000 taking placebo).  It did not find statistically significant 
differences in asthenia or impotence, and although the relationship with dizziness approached 
statistical significance, it did not reach it.55   
A systematic review and meta-analysis of studies in which men with BPH were randomly 
assigned to either daily doxazosin or placebo for at least four weeks duration in men showed a 
statistically significant difference in the relative risk ratio between the respective groups in the 
percentage of men experiencing dizziness (1.92, 95% confidence interval: 1.40 – 2.61, from five 
studies looking at 1450 men taking doxazosin and 693 taking placebo), asthenia (3.33, 95% 
confidence interval: 1.97 – 5.61, from five studies looking at 1450 men taking doxazosin and 693 
taking placebo, postural hypotension (2.72, 95% confidence interval: 1.21 – 6.15, from 4 studies 
looking at 1400 men taking doxazosin and 643 taking placebo, and somnolence (2.31, 95% 
confidence interval: 1.02 – 5.21, from 2 studies looking at 471 men taking doxazosin and 412 
taking placebo.56 
 
Side effects of 5-alpha reductase inhibitors 
Several groups have shown the development of sexual side effects after treatment with 
finasteride.  Uygur et al. showed that in 48 men with BPH taking 5 mg finasteride daily for six 
months, erectile dysfunction developed in eight men (22%) at three months and in twelve men 
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(33%) at six months.57  Nickel et al. randomized 472 BPH patients to daily treatment with either 
5 mg finasteride or placebo and found that, after two years, 7.7% of men in the finasteride group 
versus 1.7% of men in the placebo group experienced ejaculation disorders, while 15.8% versus 
6.3% experienced impotence (p<0.01 for each).58 Tenover et al. randomized 2112 men with 
symptomatic BPH to either 5 mg finasteride daily (1736 subjects) or placebo (579 subjects) for 
one year and found statistically significant differences between these groups in overall sexual 
adverse events (12.3% vs. 6.0%, p<0.001), impotence (7.4% vs. 3.3%, p<0.001), decreased 
libido (4.9% vs. 2.9%, p=0.038), and ejaculation disorder (3.3% vs. 0.9%, p=0.001).59 However, 
only 2.2% of men taking the finasteride withdrew from the study due to experience an adverse 
sexual event.   
Finally, the Proscar Long-Term Efficacy and Safety Study Group randomized 3040 
patients with moderate-to-severe urinary symptoms due to BPH and enlarged prostate glands to 
daily treatment with either 5 mg finasteride or placebo and found that after one year men in the 
finasteride group had statistically significant differences as compared to placebo in the 
occurrence of decreased libido (6.4% vs. 3.4%, p=0.002), impotence (8.1% vs. 3.7%, p<0.001), 
decreased ejaculate volume (3.7 vs. 0.8, p<0.001), and ejaculation disorders (0.8% vs. 0.1%, 
p=0.002).60  A later analysis of the results of this study reported that drug-related sexual side 
effects occurred in the first year in 15% of those taking finasteride, versus 7% of those taking 
placebo (p<0.001).61  In years two to four, however, the investigators found no statistically 
significant difference in occurrence of sexual side effects between groups. 
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Table 1:  Studies of intraprostatic injection of absolute ethanol to treat BPH: 
Published Articles Year Study Design Number and Type of Patients 
Route of 
Injection 
Quality 
Rating 
Savoca et al.36 2001 
Nonrandomized 
interventional 
(“before-and-after”) 
8 men with symptomatic 
BPH judged to be high-risk 
during preoperative 
anesthesiological evaluation 
Transperineal 6 
Ditrolio et al.37 2002 
Nonrandomized 
interventional 
(“before-and-after”)  
15 men with documented 
outlet obstruction secondary 
to BPH 
Transurethral 6 
Plante et al.38 2002 
Nonrandomized 
interventional 
(“before-and-after”)  
5 men with symptomatic 
BPH Transurethral 19 
Goya et al.39 2004 
Nonrandomized 
interventional 
(“before-and-after”)  
34 men with symptomatic 
BPH with follow-up of at 
least 3 years 
Transurethral 8 
Grise et al.40 2004 
Nonrandomized 
interventional 
(“before-and-after”)  
115 men with symptomatic 
BPH from 15 European 
centers, 94 with results at 1 
year 
Transurethral 11 
Plante et al.41 2007 
Randomized 
interventional 
(“before-and-after”)  
 
79 men with BPH, 
randomized to three different 
dosing groups per range of 
prostate size 
Transurethral 10 
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Table 2:  Studies of intraprostatic injection of botulinum toxin to treat BPH: 
Published Studies Year Study Design Number and Type of Patients Quality Rating 
Maria et al.42 2003 
Randomized, double-
blind, placebo-controlled 
clinical trial 
30 men with symptomatic BPH 
(15 Botox and 15 saline) who 
had failed medical treatment 
and refused surgery  
12 
Chuang et al.43 2005 
Nonrandomized 
interventional (“before-
and-after”)  
16 men with symptomatic BPH 
and prostates less than 30cm3 
and no response to at least 1 
month of alpha-blocker 
therapy 
9 
Kuo44 2005 
Nonrandomized 
interventional (“before-
and-after”)  
 
10 patients with symptomatic 
BPH and severe medical 
disease that prohibited them 
from surgery 
9 
Park et al.46 2006 Randomized clinical trial 
52 patients with symptomatic 
BPH who failed medical 
treatment and refused surgery  
11 
Chuang et al.45 2006 
Nonrandomized 
interventional (“before-
and-after”)  
41 patients with symptomatic 
BPH and history of failure on 
alpha-AR antagonists 
11 
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Table 3:  Quality ratings for studies included in this systematic review 
a.  Studies of intraprostatic injection of absolute ethanol: 
Study 
Source population adequately 
described with inclusion and 
exclusion criteria clearly 
stated? 
Patient flow   
clear and  
adequately 
described? 
Appropriate use of 
control group? 
Appropriate 
design and 
analysis? 
Results reported 
adequately, with p-
values and/or CI? 
Overall Quality Score 
Savoca et al.36 1 1 0 1 3 6 
Ditrolio et al.37 2 3 0 1 0 6 
Plante et al.38 3 2 0 2 2 9 
Goya et al.39 2 2 0 2 2 8 
Grise et al.40 3 3 0 2 3 11 
Plante et al.42 3 3 0 2 2 10 
 
b.  Studies of intraprostatic injection of botulinum toxin: 
Study 
Source population adequately 
described with inclusion and 
exclusion criteria clearly 
stated? 
Patient flow   
clear and  
adequately 
described? 
Appropriate use of 
control group? 
Appropriate 
design and 
analysis? 
Results reported 
adequately, with p-
values and/or CI? 
Overall Quality Score 
Maria et al.43 2 2 3 3 2 12 
Chuang et al.44 2 3 0 2 2 9 
Kuo45 2 3 0 2 2 9 
Park et al.47 2 3 1 3 2 11 
Chuang et al.46 2 3 0 2 2 11 
Each study was rated 0-3 for each category with 0 = poor, 1 = fair, 2 = good, 3 = excellent.  
Each study received a summed Overall Quality Score, which was graded as 0-3 = poor, 4-7 = fair, 8-11 = good, 12-15 = excellent. 
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Table 4:  Change in AUA/IPSS Symptom score (0 – 35) after intraprostatic injection of absolute ethanol [mean ± SD] 
Study Baseline N Baseline 1 mo 3 mo 6 mo 1 year 2 year 3 year 
Savoca et al.36 8 21±5.2  10±4.4 (p<0.0001)a 
9±4.2 
(NS)b    
Ditrolio et al.37 15 22.4 
10.3 
(n=14) 
(NA) 
5.5 
(n=13) 
(NA) 
5.6 
(n=13) 
(NA) 
5.9 
(n=13) 
(NA) 
  
Plante et al.38 5 23.4±5.0 14.2±6.6 (NA) 
12.2±5.0 
(NA) 
11.4±7.5 
(NA) 
13.8±6.8 
(p<0.05)a   
Goya et al.39 34 21.8±5.9 
14.3±7.8 
(n=33) 
(p<0.001)a 
10.4±5.3 
(n=34) 
(p<0.001)a 
10.8±5.3 
(n=33) 
(p<0.001)a 
9.6±4.6 
(n=29) 
(p<0.001)a 
10.4±5.8 
(n=19) 
(p<0.001)a 
13.1±6.2 (n=17) 
(p<0.01)a 
Grise et al.40 114 20.6±5.9 
13.7±7.1 
(n=104) 
(p<0.05)a 
10.3±6.6 
(n=94) 
(p<0.05)a 
10.6±6.3 
(n=93) 
(p<0.05)a 
10.3±6.2 
(n=93) 
(p<0.05)a 
  
 
Plante et al.41 
 
Dose 1 
 
 
 
Dose 2 
 
 
 
Dose 3 
 
 
 
27 
 
 
 
25 
 
 
 
27 
 
 
 
 
22.7±5.2 
 
 
 
24.4±5.2 
 
 
 
23.7±5.0 
 
 
 
 
 
 
 
 
12.1±7.8 
(n=26) 
(p<0.05)a 
 
11.0±8.6 
(n=22) 
(p<0.05)a 
 
11.2±4.9 
(n=24) 
(p<0.05)a 
   
NS = not significant; NA = statistical analysis not performed; aAs compared to baseline value;  bAs compared to value at 3 months 
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Table 4 (cont.):  Change in AUA/IPSS Symptom score (0 – 35) after intraprostatic injection of botulinum toxin [mean ± SD] 
Study Baseline N Baseline 1 mo 3 mo 6 mo 1 year 2 year 3 year 
Maria et al.42 15 23.2±4.1 
10.6±1.7 
(p=0.00001)a 
(p<0.05)b 
 
9.1±3.0 
(n=17)c 
(NA) 
8.9±3.2 
(n=17)c 
(NA) 
  
Chuang et al.43 16 18.8±1.6 8.9±1.9 (p<0.05)a 
7.9±1.7 
(p<0.05)a 
7.4±1.8 
(p<0.05)a    
Park et al.46 
 
26 
 
52 
 
23 
 
24.2±8.7 
 
24.3±7.8 
 
24.0±8.3 
18.5±8.2 
(p=0.001)a 
 
 
 
 
 
16.9±6.4 
(p<0.05)a 
 
 
 
 
 
 
14.7±6.0 
(p<0.05)a 
   
 
Chuang et al.45 
 
Dose 1 (100 U) 
 
 
 
Dose 2 (200 U) 
 
 
 
21 
 
 
 
20 
 
 
 
 
18.7±1.3 
 
 
 
19.3±1.2 
 
 
 
9.8±1.3  
(n=21) 
(p<0.05)a 
 
9.5±2.0  
(n=20) 
(p<0.05)a 
 
 
8.1±1.6 
(n=19) 
(p<0.05)a 
 
8.3±2.0 
(n=17) 
(p<0.05)a 
 
 
7.3±2.0 
(n=18) 
(p<0.05)a 
 
5.2±1.1 
(n=15) 
(p<0.05)a 
 
 
9.0±2.4 
(n=13) 
(p<0.05)a 
 
8.3±1.9 
(n=11) 
(p<0.05)a 
  
NA = statistical analysis not performed; aAs compared to baseline value; bAs compared to value in control group at the same time point;  cFour patients 
crossed over from the saline control group 
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Table 5: Change in QOL Index (0 – 6) after intraprostatic injection of absolute ethanol [mean ± SD] 
Study Baseline N Baseline 1 mo 3 mo 6 mo 1 year 2 year 3 year 
Plante et al.38 5 4.0±0.7 2.4±0.9 (NA) 
1.6±0.9 
(NA) 
2.2±1.6 
(NA) 
2.8±0.8 
(p<0.05)a   
Goya et al.39 34 5.0±0.6 (p<0.001)a 
3.4±1.5 
(n=33) 
(p<0.001)a 
2.6±1.4 
(n=34) 
(p<0.001)a 
2.7±1.4 
(n=33) 
(p<0.001)a 
2.3±1.4 
(n=29) 
(p<0.001)a 
2.4±1.4 
(n=19) 
(p<0.001)a 
2.8±1.3 
(n=17) 
(p<0.001)a 
Grise et al.40 114 4.4±0.8 
2.8±1.6 
(n=104) 
(p<0.05)a 
2.2±1.5 
(n=94) 
(p<0.05)a 
2.3±1.4 
(n=93) 
(p<0.05)a 
2.1±1.3 
(n=93) 
(p<0.05)a 
  
 
Plante et al.41 
 
Dose 1 
 
 
 
Dose 2 
 
 
 
Dose 3 
 
 
 
 
27 
 
 
 
25 
 
 
 
27 
 
 
 
 
4.5±0.9 
 
 
 
4.4±1.0 
 
 
 
4.2±0.9 
 
  
 
 
2.2±1.7 
(n=25) 
(p<0.05)a 
 
2.2±1.6 
(n=22) 
(p<0.05)a 
 
2.1±1.2 
(n=25) 
(p<0.05)a 
   
NA = statistical analysis not performed; aAs compared to baseline value
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Table 5 (cont.): Change in QOL Index (0 – 6) after intraprostatic injection of botulinum toxin [mean ± SD] 
Study Baseline N Baseline 1 mo 3 mo 6 mo 1 year 2 year 3 year 
Chuang et al.43 16 3.8±0.3 2.1±0.3 (p<0.05)a 
1.9±0.3 
(p<0.05)a 
1.8±0.3 
(p<0.05)a    
Kuo44 10 4.5±2.7  2.3±2.3 (p<0.0001)a 
2.1±1.9 
(p<0.0001)a    
Park et al.46 
 
26 
 
52 
 
23 
 
4.6±0.9 
 
4.8±0.9 
 
4.7±1.0 
3.4±1.3 
(p<0.05)a 
 
 
 
 
 
3.2±1.2 
(p<0.05)a 
 
 
 
 
 
 
3.0±0.8 
(p<0.05)a 
   
 
Chuang et al.45 
 
Dose 1 (100 U) 
 
 
 
Dose 2 (200 U) 
 
 
 
 
21 
 
 
 
20 
 
 
 
 
3.9±0.3 
 
 
 
4.1±0.2 
 
 
 
2.1±0.3 
(n=21) 
(p<0.05)a 
 
2.0±0.3 
(n=20) 
(p<0.05)a 
 
 
2.0±0.2 
(n=19) 
(p<0.05)a 
 
2.2±0.4 
(n=17) 
(p<0.05)a 
 
 
1.4±0.3 
(n=18) 
(p<0.05)a 
 
1.8±0.2 
(n=15) 
(p<0.05)a 
 
 
1.8±0.4 
(n=13) 
(p<0.05)a 
 
2.4±0.6 
(n=11) 
(p<0.05)a 
  
aAs compared to baseline value
McKim 38 
 
Table 6:  Change in prostate volume (ml, g, or cm3) after intraprostatic injection of absolute ethanol [mean ± SD] 
Study Baseline N Baseline 1 mo 3 mo 6 mo 1 year 2 year 3 year 
Savoca et al.36 8 40±15 ml  39±14 (NS)a 
37±13 
(NS)b    
Ditrolio et al.37 15 47.5 g  23.3 (NA) 
26.4 
(NA)    
Plante et al.38 5 53.0±19.0 ml   37.2±17.9 (p<0.05)a    
Goya et al.39 34 49.3±15.3 ml  
47.1±15.1 
(n=34) 
(p<0.001)a 
48.6±15.8 
(n=33) 
(NS)a 
45.7±16.3 
(n=29) 
(p<0.001)a 
48.9±17.8 
(n=19) 
(P<0.001)a 
51.4±21.4 
(n=17) 
(NS)a 
Grise et al.40 115 45.9±19.9 ml   
39.2±20.4 
(n=84) 
(p<0.05)a 
38.5±17.9 
(n=80) 
(p<0.05)a 
  
 
Plante et al.41 
 
Dose 1 
 
 
 
Dose 2 
 
 
 
Dose 3 
 
 
 
 
27 
 
 
 
25 
 
 
 
27 
 
 
 
46.1±15.4 ml 
 
 
 
44.3±13.3 ml 
 
 
 
45.2±12.7 ml 
  
 
 
39.8±16.2 
(n=26) 
(p<0.05)a 
 
38.7±18.3 
(n=23) 
(p<0.05)a 
 
34.0±16.0  
(n=24) 
(p<0.05)a 
   
NS = not significant; NA = statistical analysis not performed; aAs compared to baseline value; bAs compared to value at 3 months
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Table 6 (cont.):  Change in prostate volume (ml, g, or cm3) after intraprostatic injection of botulinum toxin [mean ± SD (No.)] 
Study Baseline N Baseline 1 mo 3 mo 6 mo 1 year 2 year 3 year 
Maria et al.42 15 52.6±10.6 ml 
23.8±6.2 
(p=0.0001)a 
(p<0.05)b 
 
21±7.1  
(n=17)c 
(NA) 
20.5±8  
(n=17)c 
(NA) 
  
Chuang et al.43 16 19.6±1.2 cm3 17.0±1.1 (p<0.05)a 
16.7±1.2 
(p<0.05)a 
16.9±1.1 
(p<0.05)a    
Kuo44 10 65.5±19.5 cm3  45.9±17.2 (p<0.05)a 
49.6±17.6 
(p<0.05)a    
Park et al.46 
26 
 
52 
 
23 
47.9±27.8 ml 
 
47.2±23.9 ml 
 
47.5±26.4 ml 
44.1±25.3 
(p<0.001)a 
 
 
 
 
 
 
41.0±19.0 
(p<0.05)a 
 
 
 
 
 
 
 
40.8±19.1 
(p<0.05)a 
   
 
Chuang et al.45 
 
Dose 1 (100 U) 
 
 
 
Dose 2 (200 U)  
 
 
 
21 
 
 
 
20 
 
 
 
 
21.1±1.1 ml 
 
 
 
54.3±4.7 ml 
 
 
 
18.0±1.1 
(n=21) 
(p<0.05)a 
 
46.3±3.7 
(n=20) 
(p<0.05)a 
 
 
18.0±1.0 
(n=19) 
(p<0.05)a 
 
45.0±4.2 
(n=17) 
(p<0.05)a 
 
 
17.5±0.9 
(n=18) 
(p<0.05)a 
 
45.3±4.1 
(n=15) 
(p<0.05)a 
 
 
17.0±1.6 
(n=13) 
(p<0.05)a 
 
47.2±4.0 
(n=11) 
(p<0.05)a 
  
NA = statistical analysis not performed; aAs compared to baseline value; bAs compared to value in control group at the same time point;  cFour patients 
crossed over from the saline control group
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Table 7:  Change in post-void residual volume (ml) after intraprostatic injection of absolute ethanol [mean ± SD] 
Study Baseline N Baseline 1 mo 3 mo 6 mo 1 year 2 year 3 year 
Savoca et al.36 8 130±66  27±11 (p<0.01)a 
33±9 
(NS)b    
Plante et al.38 5 118.8±102.7 97.4±84.6 (NA) 
89.8±56.5 
(NA) 
111.4±79.2 
(NA) 
111.2±76.8 
(NS)a   
Goya et al.39 34 93±61 
51±40  
(n=33) 
(p<0.001)a 
34±27  
(n=34) 
(p<0.001)a 
30±26  
(n=33) 
(p<0.001)a 
35±32 
 (n=29) 
(p<0.001)a 
23±17 
(n=19) 
(p<0.001)a 
28±20 
(n=17) 
(p<0.01)a 
 
Plante et al.41 
 
Dose 1 
 
 
 
Dose 2 
 
 
 
Dose 3 
 
 
 
27 
 
 
 
25 
 
 
 
27 
 
 
 
98.4±69.8 
 
 
 
105.1±70.8 
 
 
 
106.9±78.3 
  
 
 
97.2±75.6 
(n=26) 
(p<0.05)a 
 
88.6±87.6 
(n=23) 
(p<0.05)a 
 
79.6±65.5 
(n=23) 
(p<0.05)a 
   
NS = not significant; NA = statistical analysis not performed; aAs compared to baseline value; bAs compared to value at 3 months
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Table 7 (cont.):  Change in post-void residual volume (ml) after intraprostatic injection of botulinum toxin [mean ± SD] 
Study Baseline N Baseline 1 mo 3 mo 6 mo 1 year 2 year 3 year 
Maria et al.42 15 126.3±38.3 
49.6±13.4 
(p=0.00001)a 
(p<0.05)b 
 
24.2±17 
(n=17)c 
(NA) 
24±18 
(n=17)c 
(NA) 
  
Chuang et al.43 16 67.7±30.0 25.1±4.0 (NS)a 
27.3±4.3 
(NS)a 
26.4±4.3 
(NS)a    
Kuo44 10 243.0±133.9  53.9±20.1 (p<0.05)a 
36.8±34.1 
(p<0.05)a    
Park et al.46 
 
26 
 
52 
 
23 
 
108.1±129.6 
 
122.7±141.2 
 
108.7±126.7 
82.2±63.6 
(NS)a 
 
 
 
 
 
80.7±40.9 
(p<0.05)a 
 
 
 
 
 
 
59.4±33.4 
(p<0.05)a 
   
 
Chuang et al.45 
 
Dose 1 (100 U) 
 
 
 
Dose 2 (200 U) 
 
 
 
21 
 
 
 
20 
 
 
 
64.2±23.0 
 
 
 
161.7±48.1 
 
 
 
35.7±4.4 
(n=21) 
 (NS)a 
 
45.2±8.2 
(n=20) 
(p<0.05)a 
 
 
24.1±4.8 
(n=19) 
(p<0.05)a 
 
37.6±5.9 
(n=17) 
(p<0.05)a 
 
 
38.5±8.4 
(n=18) 
 (NS)a 
 
45.5±0.9 
(n=15) 
(p<0.05)a 
 
 
40.0±11.5 
(n=13) 
 (NS)a 
 
93.6±36.1 
(n=11) 
(NS)a  
  
NS = not significant; NA = statistical analysis not performed; aAs compared to baseline value;  bAs compared to value in control group at the same time 
point;  cFour patients crossed over from the saline control group
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Table 8:  Change in peak urinary flow rate (ml/s) after intraprostatic injection of absolute ethanol [mean ± SD (No.)] 
Study Baseline N Baseline 1 mo 3 mo 6 mo 1 year 2 year 3 year 
Savoca et al.36 8 11±3.5  16±3.1 (p<0.001)a 
17±3.4 
(NS)b    
Ditrolio et al.37 15 5.7 8.5 (NA) 
11.7 
(NA) 
11.7 
(NA) 
11.9 
(NA)   
Plante et al.38 5 9.9±2.2 13.0±3.0 (NA) 
13.8±3.6 
(NA) 
13.0±4.2 
(NA) 
13.1±3.9 
(NS)a   
Goya et al.39 34 8.3±2.8 
11.1±4.3  
(n=33) 
(p<0.001)a 
12.5±4.6 
(n=34) 
(p<0.001)a 
12.9±5.2 
(n=33) 
(p<0.001)a 
13.6±6.0 
(n=29) 
(p<0.001)a 
15.2±5.2 
(n=19) 
(p<0.001)a 
12.7±3.4 
(n=17) 
(p<0.01)a 
Grise et al.40 115 9.9±2.9 
12.8±13.8 
(n=108) 
(p<0.05)a 
13.4±5.7 
(n=105) 
(p<0.05)a 
13.4±8.6 
(n=93) 
(p<0.05)a 
13.4±5.8 
(n=90) 
(p<0.05)a 
  
 
Plante et al.41 
 
Dose 1 
 
 
 
Dose 2 
 
 
               
Dose 3 
 
 
27 
 
 
 
25 
 
 
 
27 
 
 
8.3±2.6 
 
 
 
8.1±2.2 
 
 
 
8.6±2.1 
  
 
 
11.5±5.1 
(n=20) 
(p<0.05)a 
 
13.5±6.6 
(n=21) 
(p<0.05)a 
 
16.7±10.7 
(n=22) 
(p<0.05)a 
   
NS = not significant; NA = statistical analysis not performed; aAs compared to baseline value  bAs compared to value at 3 months
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Table 8 (cont.):  Change in peak urinary flow rate (ml/s) after intraprostatic injection of botulinum toxin [mean ± SD (No.)] 
Study Baseline N Baseline 1 mo 3 mo 6 mo 1 year 2 year 3 year 
Maria et al.42 15 8.1±2.2 
14.9±2.1 
(p=0.00001)a 
(p<0.05)b 
 
14.6±4.1 
(n=17)c 
(NA) 
15±2.9 
(n=17)c 
(NA) 
  
Chuang et al.43 16 7.3±0.7 11.8±0.8 (p<0.05)a 
11.9±1.1 
(p<0.05)a 
12.5±1.0 
(p<0.05)a    
Kuo44 10 7.6±3.9  9.9±3.2 (p<0.05)a 
11.6±3.5 
(p<0.05)a    
Park et al.46 
 
26 
 
52 
 
23 
 
9.1±5.9 
 
9.6±6.5 
 
7.4±3.6 
10.1±5.6 
(NS)a 
 
 
 
 
 
11.1±5.9 
(p<0.05)a 
 
 
 
 
 
 
9.4±3.1 
(p<0.05)a 
   
 
Chuang et al.45 
 
Dose 1 (100 U) 
 
 
 
Dose 2 (200 U) 
 
 
 
 
21 
 
 
 
20 
 
 
 
 
7.9±0.6 
 
 
 
7.0±1.1 
 
 
 
12.0±0.8  
(n=21) 
(p<0.05)a 
 
10.3±1.1 
 (n=20) 
(p<0.05)a 
 
 
12.7±1.5 
(n=19) 
(p<0.05)a 
 
9.8±1.1  
(n=17) 
(p<0.05)a 
 
 
12.7±1.1 
(n=18) 
(p<0.05)a 
 
11.9±0.9 
(n=15) 
(p<0.05)a 
 
 
13.4±0.8 
(n=13) 
(p<0.05)a 
 
11.1±0.9 
(n=11) 
(p<0.05)a 
  
NS = not significant; NA = statistical analysis not performed; aAs compared to baseline value;  bAs compared to value in control group at the same time 
point; cFour patients crossed over from the saline control group
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Table 9:  Abstracts from Scientific Meetings of studies using intraprostatic injections to treat BPH 
 
 
Published Abstracts Year Agent 
Watson et al.59 1999 Absolute Ethanol 
Martinez-Sagarra, et al.60 2001 Absolute Ethanol 
Lima et al.61 2002 Absolute Ethanol 
Palmer62 2002 Absolute Ethanol 
Pauer et al.63 2002 Absolute Ethanol 
Argirovic64 2003 Absolute Ethanol 
Gutierrez-Aceves65 2003 Absolute Ethanol 
Plante et al.66 2003 Absolute Ethanol 
Matheus et al.67 2004 Absolute Ethanol 
Faur et al.68 2005 Absolute Ethanol 
Gutierrez69 2005 Absolute Ethanol 
Tabassi70 2005 Absolute Ethanol 
Bafaloukas et al.71 2006 Absolute Ethanol 
Larson et al.72 2005 Botulinum Toxin 
Guercini et al.73 2005 Botulinum Toxin 
Barqawi et al.74 2007 Botulinum Toxin 
Chuang et al.75 2007 Botulinum Toxin 
 
 
 
 
 
McKim 45 
REFERENCES 
 
1. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic 
hyperplasia with age. J Urol. Sep 1984;132(3):474-479. 
2. Imperato-McGinley J, Gautier T, Zirinsky K, et al. Prostate visualization studies in males 
homozygous and heterozygous for 5 alpha-reductase deficiency. J Clin Endocrinol 
Metab. Oct 1992;75(4):1022-1026. 
3. Ziada A, Rosenblum M, Crawford ED. Benign prostatic hyperplasia: an overview. 
Urology. Mar 1999;53(3 Suppl 3a):1-6. 
4. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: 
Diagnosis and treatment recommendations. J Urol. Aug 2003;170(2 Pt 1):530-547. 
5. Madersbacher S, Alivizatos G, Nordling J, Sanz CR, Emberton M, de la Rosette JJMCH. 
EAU 2004 Guidelines on Assessment, Therapy and Follow-Up of Men with Lower 
Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction (BPH Guidelines). 
European Urology. 2004;46(5):547-554. 
6. Barry MJ, Fowler FJ, Jr., O'Leary MP, et al. The American Urological Association 
symptom index for benign prostatic hyperplasia. The Measurement Committee of the 
American Urological Association. J Urol. Nov 1992;148(5):1549-1557; discussion 1564. 
7. Barry MJ, Fowler FJ, Jr., O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK. 
Measuring disease-specific health status in men with benign prostatic hyperplasia. 
Measurement Committee of The American Urological Association. Med Care. Apr 
1995;33(4 Suppl):AS145-155. 
8. Boci R, Fall M, Walden M, Knutson T, Dahlstrand C. Home uroflowmetry: improved 
accuracy in outflow assessment. Neurourol Urodyn. 1999;18(1):25-32. 
9. Porru D, Scarpa RM, Prezioso D, Bertaccini A, Rizzi CA. Home and office uroflowmetry 
for evaluation of LUTS from benign prostatic enlargement. Prostate Cancer Prostatic 
Dis. 2005;8(1):45-49. 
10. Flanigan RC, Reda DJ, Wasson JH, Anderson RJ, Abdellatif M, Bruskewitz RC. 5-year 
outcome of surgical resection and watchful waiting for men with moderately 
symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs cooperative 
study. J Urol. Jul 1998;160(1):12-16; discussion 16-17. 
11. McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, 
finasteride, and combination therapy on the clinical progression of benign prostatic 
hyperplasia. N Engl J Med. Dec 18 2003;349(25):2387-2398. 
12. Etzioni RD, Howlader N, Shaw PA, et al. Long-term effects of finasteride on prostate 
specific antigen levels: results from the prostate cancer prevention trial. J Urol. Sep 
2005;174(3):877-881. 
13. Hoffman RM, MacDonald R, Wilt TJ. Laser prostatectomy for benign prostatic 
obstruction. Cochrane Database Syst Rev. 2004(1):CD001987. 
14. "Finasteride".  www.drugstore.com. Accessed April 20, 2007. 
15. de la Rosette JJ, Kortmann BB, Rossi C, Sonke GS, Floratos DL, Kiemeney LA. Long-
term risk of re-treatment of patients using alpha-blockers for lower urinary tract 
symptoms. J Urol. Apr 2002;167(4):1734-1739. 
16. DiSantostefano RL, Biddle AK, Lavelle JP. The long-term cost effectiveness of 
treatments for benign prostatic hyperplasia. Pharmacoeconomics. 2006;24(2):171-191. 
McKim 46 
17. DiSantostefano RL, Biddle AK, Lavelle JP. An evaluation of the economic costs and 
patient-related consequences of treatments for benign prostatic hyperplasia. BJU Int. May 
2006;97(5):1007-1016. 
18. Nickel JC. BPH: costs and treatment outcomes. Am J Manag Care. Apr 2006;12(5 
Suppl):S141-148. 
19. Plante MK, Folsom JB, Zvara P. Prostatic tissue ablation by injection: a literature review. 
J Urol. Jul 2004;172(1):20-26. 
20. Talwar GL, Pande SK. Injection treatment of enlarged prostate. Br J Surg. May 
1966;53(5):421-427. 
21. Rehman J, Landman J, Sundaram C, Clayman RV. Tissue chemoablation. J Endourol. 
Oct 2003;17(8):647-657. 
22. Littrup PJ, Lee F, Borlaza GS, Sacknoff EJ, Torp-Pedersen S, Gray JM. Percutaneous 
ablation of canine prostate using transrectal ultrasound guidance. Absolute ethanol and 
Nd:YAG laser. Invest Radiol. Oct 1988;23(10):734-739. 
23. Levy DA, Cromeens DM, Evans R, Stephens LC, von Eschenbach AC, Pisters LL. 
Transrectal ultrasound-guided intraprostatic injection of absolute ethanol with and 
without carmustine: a feasibility study in the canine model. Urology. Jun 
1999;53(6):1245-1251. 
24. Plante MK, Gross AL, Kliment J, Kida M, Zvara P. Intraprostatic ethanol chemoablation 
via transurethral and transperineal injection. BJU Int. Jan 2003;91(1):94-98. 
25. Zvara P, Karpman E, Stoppacher R, Esenler AC, Plante MK. Ablation of canine prostate 
using transurethral intraprostatic absolute ethanol injection. Urology. Sep 
1999;54(3):411-415. 
26. Livraghi T, Benedini V, Lazzaroni S, Meloni F, Torzilli G, Vettori C. Long term results 
of single session percutaneous ethanol injection in patients with large hepatocellular 
carcinoma. Cancer. Jul 1 1998;83(1):48-57. 
27. Lee MJ, Mueller PR, Dawson SL, et al. Percutaneous ethanol injection for the treatment 
of hepatic tumors: indications, mechanism of action, technique, and efficacy. AJR Am J 
Roentgenol. Jan 1995;164(1):215-220. 
28. Di Stasi M, Buscarini L, Livraghi T, et al. Percutaneous ethanol injection in the treatment 
of hepatocellular carcinoma. A multicenter survey of evaluation practices and 
complication rates. Scand J Gastroenterol. Nov 1997;32(11):1168-1173. 
29. Fontana D, Porpiglia F, Morra I, Destefanis P. Treatment of simple renal cysts by 
percutaneous drainage with three repeated alcohol injection. Urology. May 
1999;53(5):904-907. 
30. el-Diasty TA, Shokeir AA, Tawfeek HA, Mahmoud NA, Nabeeh A, Ghoneim MA. 
Ethanol sclerotherapy for symptomatic simple renal cysts. J Endourol. Jun 
1995;9(3):273-276. 
31. Cruz F, Silva C. Botulinum toxin in the management of lower urinary tract dysfunction: 
contemporary update. Current Opinion in Urology. Nov 2004;14(6):329-334. 
32. Choo MS. Investigating Botulinum Toxin A on the Functional Properties of the Prostate. 
Eur Urol. Mar 15 2007. 
33. Patel AK, Chapple CR. Botulinum toxin injection therapy in the management of lower 
urinary tract dysfunction. International Journal of Clinical Practice. Dec 2006;60:1-7. 
34. Sahai A, Khan M, Fowler CJ, Dasgupta P. Botulinum toxin for the treatment of lower 
urinary tract symptoms: a review. Neurourol Urodyn. 2005;24(1):2-12. 
McKim 47 
35. Chuang YC, Huang CC, Kang HY, et al. Novel action of botulinum toxin on the stromal 
and epithelial components of the prostate gland. J Urol. Mar 2006;175(3 Pt 1):1158-
1163. 
36. Chuang YC, Tu CH, Huang CC, et al. Intraprostatic injection of botulinum toxin type-A 
relieves bladder outlet obstruction in human and induces prostate apoptosis in dogs. BMC 
Urol. 2006;6:12. 
37. Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin 
A reduces formalin-induced pain. Pain. Jan 2004;107(1-2):125-133. 
38. Chuang YC, Yoshimura N, Wu M, et al. Intraprostatic capsaicin injection as a novel 
model for nonbacterial prostatitis and effects of botulinum toxin A. Eur Urol. Apr 
2007;51(4):1119-1127. 
39. Savoca G, De Stefani S, Gattuccio I, Paolinelli D, Stacul F, Belgrano E. Percutaneous 
ethanol injection of the prostate as minimally invasive treatment for benign prostatic 
hyperplasia: preliminary report. Eur Urol. Nov 2001;40(5):504-508. 
40. Ditrolio J, Patel P, Watson RA, Irwin RJ. Chemo-ablation of the prostate with dehydrated 
alcohol for the treatment of prostatic obstruction. J Urol. May 2002;167(5):2100-2103; 
discussion 2103-2104. 
41. Plante MK, Bunnell ML, Trotter SJ, Jackson TL, Esenler AC, Zvara P. Transurethral 
prostatic tissue ablation via a single needle delivery system: initial experience with radio-
frequency energy and ethanol. Prostate Cancer Prostatic Dis. 2002;5(3):183-188. 
42. Goya N, Ishikawa N, Ito F, Kobayashi C, Tomizawa Y, Toma H. Transurethral ethanol 
injection therapy for prostatic hyperplasia: 3-year results. J Urol. Sep 2004;172(3):1017-
1020. 
43. Grise P, Plante M, Palmer J, et al. Evaluation of the transurethral ethanol ablation of the 
prostate (TEAP) for symptomatic benign prostatic hyperplasia (BPH): a European multi-
center evaluation. Eur Urol. Oct 2004;46(4):496-501; discussion 501-492. 
44. Plante MK, Marks LS, Anderson R, et al. Phase I/II examination of transurethral ethanol 
ablation of the prostate for the treatment of symptomatic benign prostatic hyperplasia. J 
Urol. Mar 2007;177(3):1030-1035; discussion 1035. 
45. Maria G, Brisinda G, Civello IM, Bentivoglio AR, Sganga G, Albanese A. Relief by 
botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a 
randomized, placebo-controlled study. Urology. Aug 2003;62(2):259-264; discussion 
264-265. 
46. Chuang YC, Chiang PH, Huang CC, Yoshimura N, Chancellor MB. Botulinum toxin 
type A improves benign prostatic hyperplasia symptoms in patients with small prostates. 
Urology. Oct 2005;66(4):775-779. 
47. Kuo HC. Prostate botulinum A toxin injection--an alternative treatment for benign 
prostatic obstruction in poor surgical candidates. Urology. Apr 2005;65(4):670-674. 
48. Chuang YC, Chiang PH, Yoshimura N, De Miguel F, Chancellor MB. Sustained 
beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract 
symptoms and quality of life in men with benign prostatic hyperplasia. BJU Int. Nov 
2006;98(5):1033-1037; discussion 1337. 
49. Park DS, Cho TW, Lee YK, Lee YT, Hong YK, Jang WK. Evaluation of short term 
clinical effects and presumptive mechanism of botulinum toxin type A as a treatment 
modality of benign prostatic hyperplasia. Yonsei Med J. Oct 31 2006;47(5):706-714. 
McKim 48 
50. Botulinum Toxin Injection for the Management of BPH (MIST2).  
http://clinicaltrials.gov/ct/show/NCT00451191?order=1. Accessed October 3, 2007. 
51. Safety and Efficacy Study of Botulinum Toxin Type A to Treat Lower Urinary Tract 
Symptoms Due to Benign Prostatic Hyperplasia.  
http://clinicaltrials.gov/ct/show/NCT00284518?order=2. Accessed October 3, 2007. 
52. Flomax Commercial.  Available at http://www.4flomax.com/doctor/tv.jsp. Accessed 
April 19, 2007. 
53. Weintraub A. When the Going Gets Tough. Business Week (Online Edition). [March 12, 
2007; Available at 
http://www.businessweek.com/print/magazine/content/07_11/b4025058.htm. Accessed 
April 19, 2007. 
54. Milani S, Djavan B. Lower urinary tract symptoms suggestive of benign prostatic 
hyperplasia: latest update on alpha-adrenoceptor antagonists. BJU Int. Jun 2005;95 Suppl 
4:29-36. 
55. MacDonald R, Wilt TJ. Alfuzosin for treatment of lower urinary tract symptoms 
compatible with benign prostatic hyperplasia: a systematic review of efficacy and adverse 
effects. Urology. Oct 2005;66(4):780-788. 
56. MacDonald R, Wilt TJ, Howe RW. Doxazosin for treating lower urinary tract symptoms 
compatible with benign prostatic obstruction: a systematic review of efficacy and adverse 
effects. BJU Int. Dec 2004;94(9):1263-1270. 
57. Uygur MC, Arik AI, Altug U, Erol D. Effects of the 5 alpha-reductase inhibitor 
finasteride on serum levels of gonadal, adrenal, and hypophyseal hormones and its 
clinical significance: a prospective clinical study. Steroids. Apr 1998;63(4):208-213. 
58. Nickel JC, Fradet Y, Boake RC, et al. Efficacy and safety of finasteride therapy for 
benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the 
PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study. Cmaj. Nov 
1 1996;155(9):1251-1259. 
59. Tenover JL, Pagano GA, Morton AS, Liss CL, Byrnes CA. Efficacy and tolerability of 
finasteride in symptomatic benign prostatic hyperplasia: a primary care study. Primary 
Care Investigator Study Group. Clin Ther. Mar-Apr 1997;19(2):243-258. 
60. McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute 
urinary retention and the need for surgical treatment among men with benign prostatic 
hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med. Feb 
26 1998;338(9):557-563. 
61. Wessells H, Roy J, Bannow J, et al. Incidence and severity of sexual adverse experiences 
in finasteride and placebo-treated men with benign prostatic hyperplasia. Urology. Mar 
2003;61(3):579-584. 
62. Watson RA, Patel P, Di Trolio JV. Transurethral ethanol ablation of the prostate. Journal 
of Urology. April 1999;161(4 SUPPL.):305. 
63. Martinez-Sagarra J, Conde C, Amen J, Estebanez J, Rodriguez-Toves L, Alonso D. 
Ethanol in BPH: Preliminary results. Journal of Endourology. November 
2001;15(Supplement 1):A44. 
64. Lima M, Netto N, Jr., Larson T, et al. Intraprostatic alcohol gel injection for the treatment 
of Benign Prostatic hyperplasia preliminary results. European Urology Supplements. 
2002;1(1):130. 
McKim 49 
65. Palmer J, Subramonian K, Keen M. Prostaject ethanol injection therapy for benign 
prostatic hyperplasia- 12 month results. European Urology Supplements. 2002;1(1):131. 
66. Pauer P, Woo H, Mazza O, Gilling P, Gutierrez J. Transurethral Ethanol Ablation of the 
Prostate (TEAP), initial report of a prospective multi-centre study. European Urology 
Supplements. 2002;1(1):130. 
67. Argirovic D. Day-case transurethral ethanol ablation of the prostate (teap): early 
experience. J Endourol. 2003;17(supplement 1):A158. 
68. Gutierrez-Aceves J, Gilling P, Schettini M, Grise P, Martinez Sagarra J, Hernandez C. 
Transurethral ethanol ablation of the prostate (TEAP), initial long term report of two 
prospective multi-centre studies. Journal of Urology. April 2003;169(4 Supplement):466. 
69. Plante M, Baena V, Ballanger P, et al. Evaluation of transurethral anhydrous alcohol 
injection for symptomatic benign prostatic hyperplasia (BPH) -- An european multi-
center experience. European Urology Supplements. 2003;2(1):103. 
70. Matheus WE, Leitao VA, Lima ML, et al. Transurethral, transperineal and transrectal 
ethanol gel injection for the treatment of benign prostatic hyperplasia: A prospective 
study of 52 patients. Journal of Urology. Apr 2004;171(4):400-400. 
71. Faur SE, Surur DM, Staneloni ES, et al. Prostate ethanol chemoablation for BPH. 
Urology. 2005;66(3, Supplement 1):19-20. 
72. Gutierrez J, Fonseca R, Hurtado F, Lozano F, Mues E. Transurethral ethanol ablation of 
the prostate (TEAP) in patients with acute urinary retention. Journal of Endourology. 
Aug 2005;19(Suppl. 1):A43. 
73. Tabassi KT, Taghavi R, Keshvari M. Ethanol injection into the median lobe of the 
prostate for treatment of benign prostatic hyperplasia. Journal of Endourology. Aug 
2005;19(Suppl. 1):A44. 
74. Bafaloukas N, Staios D, Zammit P, et al. Transurethral ethanol ablation treatment for 
BPH. Journal of Endourology. Aug 2006;20(Suppl. 1):A319. 
75. Larson TR, Huidobro C, Acevedo C, Mynderse LA, Larson B. Intraprostatic injection of 
botulinum toxin in the treatment of symptomatic LUTS, including sequential MRIs for 
accurate changes in size of the prostate. Journal of Urology. Apr 2005;173(4, Suppl. 
S):376. 
76. Guercini F, Giannantoni A, Bard RL, et al. Intraprostatic botulin toxin injection in 
patients with severe benign prostatic hyperplasia - A multicenter feasibility study. 
Journal of Urology. Apr 2005;173(4, Suppl. S):376-377. 
77. Barqawi AB, Lugg J, Wilson S, Kim F, Crawford ED. Phase 1 dose escalation clinical 
trial of intraprostatic injection of botulinum toxin type A in men with obstructive luts due 
to benign prostatic hyperplasia. Journal of Urology. Apr 2007;177(4):514-514. 
78. Chuang YC, Chiang PH, Yoshimura N, Chancellor MB, Hsien KS. Efficacy and length 
of symptom improvement after botulinum toxin type A injection in BPH patients not 
correlated with change in prostate volume. Journal of Urology. Apr 2007;177(4):610-
610. 
 
 
